MICA/MICB-Mediated NKG2D Immune Escape in Cervical Cancer: Single-Cell Transcriptomic Mapping of Radionuclide Therapy Targets for Precision Radioimmunotherapy
Cervical cancer cells evade immune attack through specific mechanisms that researchers identified, opening possibilities for targeted radioimmune therapy strategies.
This study integrated single-cell RNA sequencing with experimental validation to characterize how cervical cancer evades NKG2D-mediated innate immunity via MICA/MICB dysregulation, and identified translational targets for NKG2D-directed radionuclide therapy. The findings support a theranostic application of NKG2D-targeting probes for patient stratification in radioimmunotherapy.
What the study was
- Study design
- scRNA-seq analysis + experimental validation
- Population
- Cervical cancer patients (scRNA-seq datasets); cell line validation
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer Biotherapy and Radiopharmaceuticals
Why it surfaced
Novel theranostic approach combining scRNA-seq biology with radionuclide targeting. Score limited by pre-clinical nature and abstract-only access.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.